medigraphic.com
ISSN 1405-1699 (Impreso)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2012, Número 1

<< Anterior Siguiente >>

Alerg Asma Inmunol Pediatr 2012; 21 (1)


Enfermedad de Kawasaki, ¿una enfermedad exótica y rara?

Gámez GLB, Yamazaki-Nakashimada MA

Idioma: Español
Referencias bibliográficas: 117
Paginas: 23-35
Archivo PDF: 421.83 Kb.


RESUMEN

La enfermedad de Kawasaki es una enfermedad vasculítica presente en niños, particularmente en menores de 5 años de edad. Esta enfermedad se está diagnosticando en México cada vez con mayor frecuencia. El espectro clínico se ha ampliado, así como las posibilidades terapéuticas. Mostramos la experiencia en un hospital de tercer nivel así como los avances recientes en esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kawasaki T et al. A New infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271-6.

  2. Kushner HI, Burns JC et al. The histories of Kawasaki disease. Progress Pediatric Cardiology 2004; 19: 91-97.

  3. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheum 2011; 20(9): 17.

  4. Kushner HI, Abramowsky CR. An old autopsy report sheds light on a “New” disease: infantile polyarteritis nodosa and Kawasaki disease. Pediatr Cardiol 2010; 31: 490-6.

  5. Rodríguez-Herrera R y cols. Enfermedad de Kawasaki. Acta Pediatr Mex 2001; 22: 97-103.

  6. Rodríguez SR. Síndrome linfomucocutáneo. Bol Med Hosp Infant Mex 1977; 34: 53-57.

  7. Castañeda JL y cols. Enfermedad de Kawasaki: evolución clínica cambiante que hace dudar al clínico. Rev Enf Inf Pediatric (Mex) 1988; 1: 103-205.

  8. Vizcaíno A. Enfermedad de Kawasaki en niños mexicanos. Bol Med Hosp Infant Mex 1991; 48: 398-408.

  9. González-Galnares M y cols. Enfermedad de Kawasaki en México: análisis de 13 casos. Bol Med Hosp Infant Mex 1991; 48: 409-416.

  10. Norberto SN, González LA. Kawasaki disease: A rare pediatric pathology in Mexico. Twenty cases report from the Hospital Infantil del Estado de Sonora. Arch de Cardiol de Mex 2007; 77: 299-307.

  11. Frenkel SM y cols. Enfermedad de Kawasaki: Experiencia con ocho casos del Centro Médico ABC. Anales Médicos 2004; 49: 66-72.

  12. Soto K, Santigeral P, Gaytán G, Valenzuela A y cols. Enfermedad de Kawasaki. Prevalencia en el Hospital Infantil Privado. Revista de Enfermedades Infecciosas en Pediatría 2011: 95.

  13. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008; 40: 35-42.

  14. Onouchi Y, Onoue S, Tamari M, Wakui K, Fukushima Y, Yashiro M et al. CD40 ligand gene and Kawasaki disease. Eur J Hum Genet 2004; 12: 1062-8.

  15. Breunis WB, Biezeveld MH, Geissler J, Kuipers IM, Lam J, Ottenkamp J, Hutchinson A, Welch R, Chanock SJ, Kuijpers TW. Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease. Clin Exp Immunol 2007; 150: 83-90.

  16. Onouchi Y. Molecular genetics of Kawasaki disease. Pediatr Res 2009; 65: 46-54.

  17. Newburger JW et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708-33.

  18. Climaz R et al. Atypical and incomplete Kawasaki disease: best practice and research. Clinical Rheumatology 2009; 23: 689-698.

  19. Parra-Moronatti P, Rivera-Rodríguez L, Yamazaki-Nakashimada MA, Nava-García F, Rodríguez-Álvarez J, Bolaños-Reyes R. Refractory, incomplete, and atypical Kawasaki disease. Case report and review of the literature. Arch Cardiol Mex 2011; 81: 221-7.

  20. Forsey J, Mertens L. Atypical Kawasaki disease- a clinical challenge. Eur J Pediatr 2011, on line.

  21. Sudo D et al. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. Eur J Pediatr 2011, on line.

  22. Huang MY et al. Acute phase reactants and a supplemental diagnostic aid for Kawasaki disease. Pediatr Cardiol 2010; 31: 1209-1213.

  23. Kritsaneepaiboon S et al. Atypical presentation of Kawasaki disease in young infants mimicking a retropharyngeal abscess. Emer Radiol 2011, on line.

  24. Uehara R et al. Kawasaki disease patients with redness or crust formation at the bacilli Calmette-Guerin inoculation site. Pediatr Infect Dis J 2010; 29: 430-3.

  25. García-Pavón S et al. Reactivation of the scar of BCG vaccination in Kawasaki disease: clinical case and literature review. Rev Alerg Mex 2006; 53: 76-8.

  26. Baker AL, Lu M, Minich LL, Atz AM, Klein GL, Korsin R et al. Associated symptoms in the ten days prior to diagnosis of Kawasaki disease. J Pediatr 2009; 154: 592-4.

  27. Yun SH, Yang NR, Park SA. Associated symptoms of Kawasaki disease. Korean Circ J 2011; 41: 394-398.

  28. Rodríguez-Lozano AL, Rivas-Larrauri FE, Hernández-Bautista VM, Yamazaki-Nakashimada MA. Fever is not always present in Kawasaki disease. Rheumatol Int 2011.

  29. Saltigeral-Simental P et al. Kawasaki disease: must fever be obligatory criterion? Rev Alerg Mex 2008; 55: 176-9.

  30. Zulian F, Falcini F, Zancan L et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr 2003; 142: 731-5.

  31. Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr 1996; 128: 701-3.

  32. Gong GWK et al. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr 2006; 148: 800-5.

  33. Ueno et al. Potential role of autoantibody in severe neutropenia of a patient with Kawasaki syndrome. Scand J Immunol 2012; 75: 120-6.

  34. Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC. Evolution of laboratory values in patients with Kawasaki disease. Pediatr Infect Dis J 2011; 30: 1022-6.

  35. Weng KP, Hsieh KS, Huang SH et al. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease. Kaohsiung J Med Sci 2012; 28: 23-9.

  36. Huang MY, Gupta, Malhotra M, Huang JJ et al. Acute-phase reactants and a supplemental diagnostic aid for Kawasaki disease. Pediatr Cardiol 2010; 31: 1209-13.

  37. Yoshikawa H et al. Serum procalcitonin value is useful for predicting severity of Kawasaki disease. Pediatr Infect Dis J 2011.

  38. Okada Y et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 2004; 48: 199-203.

  39. Manlhiot C, Yeung RS, Clarizia NA, Chahal N, McCrindle BW. Kawasaki disease at the extremes of age spectrum. Pediatrics 2009; 124: 410-415.

  40. Yamazaki-Nakashimada MA et al. Chronic granulomatous disease associated with atypical Kawasaki disease. Pediatr Cardiol 2008; 29: 169-71.

  41. Diniz JC et al. Kawasaki disease and juvenile systemic lupus erythematosus. Lupus 2012; 21:89-92.

  42. Gámez-González LB y cols. Enfermedad de Kawasaki y púrpura de Henoch-Schoenlein: dos vasculitis frecuentes en una asociación infrecuente. Rev Alergia Mex 2012 (en prensa).

  43. Kawakami C, Miyake M, Tamai H. Kawasaki disease in a patient with Wiskott-Aldrich syndrome: an increase in the platelet count. Int J Hematol 2003; 77: 199-200.

  44. Ling JC, Freeman AF, Gharib AM, Arai AE, Lederman RJ, Rosing DR et al. Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. Clin Immunol 2007; 122: 255-8.

  45. Johnson RM, Little JR, Storch GA. Kawasaki-like syndromes associated with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 1628-34.

  46. Behniafard N, Aghamohammadi A et al. Autoimmunity in X-linked agammaglobulinemia: Kawasaki disease and review of the literature. Expert Rev Clin Immunol 2012; 8: 155-9.

  47. Webster RJ, Carter KW, Warrington NM, Loh AM, Zaloumis S et al. Hospitalization with infection, asthma and allergy in Kawasaki disease patients and their families: genealogical analysis using linked population data. PLoS ONE 2011; 6(11): e28004.

  48. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967; 16: 178-222.

  49. Brosius DL, Newburger JW, Burns JC et al. Increased prevalence of atopic dermatitis in Kawasaki disease. Pediatr Infect Dis J 1988; 7: 863-6.

  50. Liew WK, Lim CWT, Tan TH, Wong KY, Tai BC, Quek SC, Bever HV. The effect of Kawasaki disease on childhood allergies –a sibling control study. Pediatric Allergy Immunology 2011; 22: 488-493.

  51. Burgner D, Carter K, Webster et al. Kawasaki disease, childhood allergy and the hygiene hypothesis. Pediatr Allergy Immunol 2011; 22: 751.

  52. Henter JI, Horne A, Arico M et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-131.

  53. Hyun Kwon Kim, Han Gyu Kim, Su Jin Cho et al. Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease. Pediatric Hematology and Oncology 2011; 28: 230-236.

  54. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003; 112: 495.

  55. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003; 112(6 Pt 1): 495-497.

  56. Ohga S, Ooshima A, Fukushige J, Ueda K. Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. Eur J Pediatr 1995; 154: 539-541.

  57. Chen Y et al. Hemophagocytic lymphohistiocytosis at initiation of Kawasaki disease and their differential diagnosis. Pediatric Hematology and Oncology 2010; 27: 244-249.

  58. Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003; 22: 663-666.

  59. al-EidW, al-Jefri A, Bahabri S, al-Mayouf S. Hemophagocytosis complicating Kawasaki disease. Pediatr Hematol Oncol 2000; 17: 323-329.

  60. Kaneko K, Takahashi K, Fujiwara S et al. Kawasaki disease followed by haemophagocytic syndrome. Eur J Pediatr 1998; 157: 610-611.

  61. Titze U, Janka G, Schneider EM et al. Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis. Pediatr Blood Cancer 2009; 53: 493-495.

  62. Yeon KN et al. A case of refractory Kawasaki disease complicated by peripheral ischemia. Pediatr Cardiol 2008; 29: 1110-4.

  63. Chang JS et al. Kawasaki disease complicated by peripheral gangrene. Pediatr Cardiol 1999; 20: 139-142.

  64. Gómez-Moyano E et al. Kawasaki disease complicated by cutaneous vasculitis and peripheral gangrene. J Am Ac Dermatol 2011; 64: 74-5.

  65. Foster B et al. Kawasaki disease complicated by renal artery stenosis. Arch Dis Child 2000; 83: 253-255.

  66. Falcini F et al. Bilateral renal artery stenosis in Kawasaki disease: a report of two cases. Clinical and Experimental Rheumatology 2006; 24: 719-721.

  67. Cura MA, Haskal JZ, Weintraub J, Benvenisty A. SIR 2004 film panel case: systemic artery aneurysms in Kawasaki disease. Vasc Interv Radiol 2004;15: 1009-1011.

  68. Yacoe ME, Dake MD. Development and resolution of systemic and coronary artery aneurysms in Kawasaki disease. AJR Am J Roentgen 1992; 159: 708-10.

  69. Pires A, Graca-Sousa EC. Coronary and systemic aneurysms in an infant with Kawasaki. Disease Pediatr Cardiol 2009; 30: 568-569.

  70. Suda K, Matsumura M, Ohta S. Kawasaki disease complicated by cerebral infarction. Cardiol Young 2003; 13: 103-5.

  71. Fujiwara S, Yamano T, Hattori M, Fujiseki Y, Shimada M. Asymptomatic cerebral infarction in Kawasaki disease. Pediatr Neurol 1992; 8: 235-236.

  72. Satoshi Tanaka S et al. Ruptured pediatric posterior cerebral artery aneurysm 9 years after the onset of Kawasaki disease: a case report. Childs Nerv Syst 2007; 23: 701-706.

  73. Jun Hyong AJ et al. A ruptured middle cerebral artery aneurysm in a 13-month-old boy with Kawasaki disease. Case report. J Neurosurg Pediatrics 2010; 6(6): 150-153.

  74. Yamazaki-Nakashimada MA et al. Catastrophic Kawasaki disease or juvenile Polyarteritis nodosa? Semin Arthritis Rheum 2006; 35: 349-54.

  75. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Burns JC. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123; 783-789.

  76. Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glode MP. Kawasaki disease in a Pediatric Intensive Care Unit: A Case-control study. Pediatrics 2008; 122(4): 786-790.

  77. Thabet F, Bafaqihm H, Al-Mohaimeed S. Shock: an unusual presentation of Kawasaki disease. Eur J Pediatr 2011; 170: 941-943.

  78. Gatterre P, Oualha M, Dupic L. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med 2012, on line.

  79. Natterer J et al. Capillary leak leading to shock in Kawasaki disease without myocardial dysfunction. Cardiology in the Young 2011; 21: 1-4.

  80. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol 2010; 22: 551-60.

  81. Pinnaa G, Kafetzisb DA, Tselkasc O, Chrysanthi L. Kawasaki disease: an overview. Skevakib Curr Opin Infect Dis 2008; 21: 263-70.

  82. Rowley A. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010; 8(2): 197–203.

  83. Rowley AH, Shulman ST. New developments in the search for the etiologic agent of Kawasaki disease. Curr Opin Pediatr 2007; 19: 71-4.

  84. Rowley AH et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLos ONE 2008; 3: e1582.

  85. Kottek A, Shimizu C, Burns JC. Kawasaki disease in monozygotic twins. Pediatr Infect Dis J 2011; 30: 114-6.

  86. Management of Kawasaki syndrome. A Consensus Statement prepared by North American participants of the Third International Kawasaki Disease symposium. Tokio, Japan. December 1988. Pediatr Infect Dis J 1989; 8: 663-7.

  87. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003.

  88. Yamazaki-Nakashimada MA. Corticosteroides en la enfermedad de Kawasaki. Acta Pediatr Mex 2006; 27.

  89. Kobayashi T et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J 2009; 28: 498-502.

  90. Okada K, Hara J, Miki I, Miki K, Matsuzaki K, Matsuoka T, Yamamoto T, Nishigaki T, Kurotobi S, Sano T. Osaka Kawasaki disease study group (2009). Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr 2009; 168: 181-185.

  91. Okada Y, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T, Kobayashi T, Morikawa A. Gunma Kawasaki disease study group (2003). Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003; 143: 363-367.

  92. Kato H, Koike S, Yokoyama T. Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175-9.

  93. Newburger J et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. New Engl J Med 2007; 356: 663-75.

  94. Zhu BH, Lv HT, Sun L, Zhang JM, Cao L, Jia HL, Yan WH, Shen YP. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr 2011.

  95. Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K. Corticosteroid pulse combination therapy for refractory Kawasaki disease: A Randomized Trial. 2011.

  96. Shirley DA, Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin. Pediatr Infect Dis J 2010; 29: 978-9.

  97. Song MS, Lee SB, Sohn S, Oh JH, Yoon KL, Han JW et al. Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J 2010; 40: 334-8.

  98. Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011; 158: 644.

  99. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 2010; 157: 960-966.

  100. Portman M et al. Etanercept as adjunctive treatment for acute Kawasaki disease: Study design and rationale. Am Heart J 2011; 161: 494-9.

  101. McCandless RT et al. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease? Am J Cardiol 2010; 105: 1625-8.

  102. Williams RV et al. Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002; 109: e4.

  103. Imagawa T, Mori M, Miyamae T et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004; 163: 263-264.

  104. Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Takashi KM, Ishiwata T, Kobayashi T, Sato H, Takizawa M. Ulinastatin: a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: A retrospective study 2011. American Heart Association 2011; 124: 2822-8.

  105. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y et al. Long-term consequences of Kawasaki disease. A10- to 21-year follow-up study of 594 patients. Circulation Epidemiol 2008; 18: 167-172. 1996; 94: 1379-1385.

  106. Samada K et al. Grown-up Kawasaki disease patients who have giant coronary aneurysms. World J Pediatr 2010; 6: 38-42.

  107. Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996; 28: 253-7.

  108. Shaukat N, Ashraf S, Mebewu A, Freemont A, Keenan D. Myocardial infarction in a young adult due to Kawasaki disease. A case report and review of the late cardiological squeal of Kawasaki disease. Int J Cardiol 1993; 39: 222-6.

  109. Tsuda E, Arakaki Y, Shimizu T, Sakaguchi H, Yoshimura S, Yazaki S, Echigo S. Changes in causes of sudden deaths by decade in patients with coronary arterial lesions due to Kawasaki disease. Cardiol Young 2005; 15: 481-8.

  110. Suda K et al. Persistent coronary arterial inflammation in a patient long after the onset of Kawasaki disease. Int J Cardiol 2012; 154: 193-4.

  111. Tsuda E, Hirata T, Matsuo O, Abe T, Sugiyama H, Yamada O. The 30-Year outcome for patients after myocardial infarction due to coronary artery lesions caused by Kawasaki disease. Pediatr Cardiol 2011; 32: 176-182.

  112. Smith BA, Grider DJ. Sudden death in a young adult: squeal of childhood Kawasaki disease. Am J Emerg Med 1993; 114: 381-3.

  113. Canino-Rodríguez A, Cox RA. Giant coronary aneurysms in a young adult patient with Kawasaki disease. P R Health Sci J 2008; 27: 382-6.

  114. Seve P, Stankovic K, Smail A, Durand DV, Marchand G, Broussolle C. Adult Kawasaki disease: report of two cases and literature review. Semin Arthritis Rheum 2005; 34: 785-792.

  115. Tsuda E, Matsuo M, Naito H, Noguchi T, Nonogi H, Echigo S. Clinical features in adults with coronary arterial lesions caused by presumed Kawasaki disease. Cardiol Young 2007; 17: 84-9.

  116. Gomard-Mennesson E, Landron C, Dauphin C et al. Kawasaki disease in adults report of 10 cases. Medicine (Baltimore) 2010; 89: 149-58.

  117. Kanno K et al. An adult case of Kawasaki disease in a pregnant Japanese woman: a case report. Case Rep Dermatol 2011; 3: 98-102.




2020     |     www.medigraphic.com